Clinical assessment of moderate-dose glucocorticoid in the treatment of recurrence of primary nephrotic syndrome in children: a prospective randomized controlled trial
TU Juan, CHEN Chao-Ying, GENG Hai-Yun, LI Hua-Rong, XIA Hua, LIN Yuan, LIN Tian-Tian, SUN Jin-Shan
Department of Nephrology, Children's Hospital Affiliated to Capital Institute of Pediatrics, Beijing 100020, China (Chen C-Y, Email: chenchaoying484@aliyun.com)
Abstract Objective To study the clinical effect and adverse drug reactions of different doses of glucocorticoid (GC) in the treatment of children with recurrence of steroid-sensitive nephrotic syndrome (SSNS). Methods A total of 67 children who were hospitalized and diagnosed with SSNS recurrence in the Department of Nephrology, Children's Hospital, Capital Institute of Pediatrics, from November 2017 to December 2019 were enrolled. They were randomly divided into a moderate-dose GC group (32 children) and a full-dose GC group (35 children). The two groups were compared in terms of urinary protein clearance, recurrence rate within 6 months, and incidence rate of GC-associated adverse reactions. Results There was no significant difference in the urinary protein clearance rate between the moderate-dose GC and full-dose GC groups (91% vs 94%, P>0.05). There was also no significant difference in the recurrence rate within 6 months between the two groups (41% vs 36%, P>0.05). At 6 months of follow-up, compared with the full-dose GC group, the moderate-dose GC group had a significantly lower cumulative dose of prednisone [(87±18) mg/kg vs (98±16) mg/kg, P=0.039] and a significantly lower proportion of children with an abnormal increase in body weight (6% vs 33%, P=0.045). The logistic regression analysis showed that prednisone dose ≥10 mg/alternate day at enrollment was a risk factor for recurrence within 6 months in children with SSNS (P=0.018). Conclusions For children with SSNS recurrence, moderate-dose GC has similar effects to full-dose GC in the remission induction rate and the recurrence rate within 6 months, with a lower cumulative dose and fewer GC-associated adverse reactions within 6 months than full-dose GC. Citation:Chinese Journal of Contemporary Pediatrics, 2022, 24(5): 466-471
TU Juan,CHEN Chao-Ying,GENG Hai-Yun et al. Clinical assessment of moderate-dose glucocorticoid in the treatment of recurrence of primary nephrotic syndrome in children: a prospective randomized controlled trial[J]. CJCP, 2022, 24(5): 466-471.
TU Juan,CHEN Chao-Ying,GENG Hai-Yun et al. Clinical assessment of moderate-dose glucocorticoid in the treatment of recurrence of primary nephrotic syndrome in children: a prospective randomized controlled trial[J]. CJCP, 2022, 24(5): 466-471.
Pasini A, Benetti E, Conti G, et al. The Italian Society for Pediatric Nephrology (SINePe) consensus document on the management of nephrotic syndrome in children: part I—diagnosis and treatment of the first episode and the first relapse[J]. Ital J Pediatr, 2017, 43(1): 41. PMID: 28427453. PMCID: PMC5399429. DOI: 10.1186/s13052-017-0356-x.
4 KDIGO Work Group. KDIGO clinical practice guideline for glomerulonephritis[J]. Kidney Int Suppl, 2012, 2: 139-274.
Raja K, Parikh A, Webb H, et al. Use of a low-dose prednisolone regimen to treat a relapse of steroid-sensitive nephrotic syndrome in children[J]. Pediatr Nephrol, 2017, 32(1): 99-105. PMID: 27677978. DOI: 10.1007/s00467-016-3458-6.
Borovitz Y, Alfandary H, Haskin O, et al. Lower prednisone dosing for steroid-sensitive nephrotic syndrome relapse: a prospective randomized pilot study[J]. Eur J Pediatr, 2020, 179(2): 279-283. PMID: 31728673. DOI: 10.1007/s00431-019-03506-5.
Fujinaga S, Sakuraya K. Initial prednisolone dosing for the first relapse of steroid-sensitive nephrotic syndrome in Japanese children[J]. Pediatr Nephrol, 2018, 33(11): 2205-2206. PMID: 30128791. DOI: 10.1007/s00467-018-4064-6.
Kainth D, Hari P, Sinha A, et al. Short-duration prednisolone in children with nephrotic syndrome relapse: a noninferiority randomized controlled trial[J]. Clin J Am Soc Nephrol, 2021, 16(2): 225-232. PMID: 33478976. PMCID: PMC7863637. DOI: 10.2215/CJN.06140420.
Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects[J]. Ann Rheum Dis, 2009, 68(7): 1119-1124. PMID: 18684744. DOI: 10.1136/ard.2008.092163.
Santiago T, da Silva JA. Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years[J]. Ann N Y Acad Sci, 2014, 1318: 41-49. PMID: 24814757. DOI: 10.1111/nyas.12428.
Allen DB, Julius JR, Breen TJ, et al. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study[J]. J Clin Endocrinol Metab, 1998, 83(8): 2824-2829. PMID: 9709954. DOI: 10.1210/jcem.83.8.5036.
